
ah yoh, such a volatile market, worried kena heart attack, go to sign my will later on loh.
How did you base your conclusion that 0.49 is too ex ? interested to know
Using TA to analysis, we can determine the (NEVER exactly, roughly yes) price range a particular counter tends to shift to...
There are several models and tools out there so each analysis may come up with different results, but if several tools shows similarly close pattern... it raise the stake of credibility where a stock will go... mostly base on volume though...
For instance for Biosensors, somebody(or bodies) pick up quite a amt of this share on 1st Apr, and this happens again on 21st Mar, and TA + some calculations will tell you the movement ...
Hope that helps clear things up a bit
=o)
finally i get to see the counter i bought managed to squeeze into top 20 volume... happy but sad on the other hand... from 0.71 to 0.465... i hugging biosensors.... biosensors hugging me....

How did you base your conclusion that 0.49 is too ex ? interested to know.
elfinchilde ( Date: 08-Jul-2008 13:20) Posted:
|
If i am not wrong, his average cost is > 70 cents.. maybe even > 80
He averaged down alot during the Jan drop.
nextdoor ( Date: 08-Jul-2008 16:07) Posted:
|
this thread suddenly attract many people from east west north south, heeee.... seem like grabbing a lot of attention, top 20 volume today lei..
My TA shows practically new depth...
Trader88, does your TA shows the same?
Nid some pointers here
Do we keep adjusting TA with current pricing to stay current?
Or we just stick to the model that most rightfully justify the counter through backtest?
=^)
dont forget there are 4 other stems out there which have FDA approval liao.
ironside ( Date: 09-Jul-2008 13:30) Posted:
|
even at this current price i sure u r safe...... as in u did not get it....

jackjames ( Date: 09-Jul-2008 12:30) Posted:
|
Goodness, consecutive sell downs for so many sessions liao.. seems endless
oh shit... really didn't imagine it can really drop to 0.465 from my beloved 0.69...
must do cost averaging, else, waiting to hit back to 0.69 might take ages, ha ha..
DOW down, and this one opens at 0.475....
Freefall... hope Louis hold back for now... for a "better" pricing
4th Q's results for BIO showed a loss of US3.148 mill fair value adjustment on derivatives. Does anyone know how is this value derived from? is it the share price for e.g. XTENT?
Supposing BIO owns the shares of XTENT and the share price increases this Q, does this get adjusted positively?
Xtent shares rise on outlook for stent 07.09.08
NEW YORK -
Shares of medical device maker Xtent Inc. jumped Wednesday as Wall Street maintained a bullish outlook for the company's developing drug-coated stent, Custom NX.
The stock rose 47 cents, or 18 percent, to close at $3.08. Shares have traded between $2.16 and $11.12 over the last 52 weeks.
The company's stent could represent a breakthrough in treating some of the toughest heart disease cases, said RBC Capital Markets Phil Nabone, in a note to investors. He reaffirmed an "Outperform" rating with a $19 price target.
Stents are mesh-metal tubes used to prop open clogged arteries after they have been cleared of plaque and drug coatings are used to prevent the growth of scar tissue. Wall Street has been hoping for a recovery in the drug-coated stent market after years of declines because of research questioning their safety and effectiveness. A positive sign for investors was the approval of Abbott Laboratories Xience V last week.
Over the past several months, analysts have been bullish on Custom NX because of its clinical trial success and advantages to marketed stents. Doctors can customize the length and diameter of the device. But, shares are still down about 52 percent since April, and about 73 percent since the start of the year, despite the positive sentiment.
"We think the stock's weakness is mainly a reflection of the tough equity market environment, and shares of early stage, high-risk companies have been hit especially hard," Nabone said. "Additionally, we sense that some investors may have grown impatient waiting for clear signs of progress with the Food and Drug Administration and European regulators."
The delays reflect a far more cautious and deliberative approach to product reviews by regulators, the analyst said, as the specter of safety and performance issues for the devices linger. Nabone said the Custom NX stent shouldn't have any trouble living up to the new standards, citing its adjustment capabilities, ability to treat multiple lesions, and lower cost-per-procedure compared with fixed-length stents.
Since there is no support to be seen, 45 cents is possible.
of course today will test 0.45.. don't forget total about 3000 lots done deal yesterday at 0.50-0.505... heee....
LMA? At least that one is still accountable with the market flow...
but this one is not... not at all...
?_?
Will it be another LMA, I hope not.

I dunno waht to say... good luck? I think that is the last thing I will say...
trade with care Louis, several TA shows there are still some "bulk" for "dumping"...
If they are the long holders, then yeah, it will be one fine day for BIG tml
^_^
im say that buy ur limited,,,,,,,,,,must have extra bullet for bottom fishing,,,,,,,,,,,tis one is q badly hit,,,,,,,,,,,i didnt expect it was force selling today,,,,,,,,so tomorow look like sunshine day,,,,,,,,dow jones look like stable,,,,oil also within range up and down,,,,,,,,,,,so confident is back,,,,,,,,,,than hungry buyer come back again,,,,,,,,,cheap cheap lelong no more ,,,,,,,,,,,,,,,,cheeers for sunshine day coming